Medicilon congratulates MindRank's GLP-1RA small molecule oral drug for successfully administering the first subject in clinical phase I

On June 12, 2023, MindRank, which focuses on the use of AI to drive the development of new drugs, announced that the phase I clinical trial of its self-developed GLP-1RA small molecule oral drug MDR-001 successfully completed the first subject administration. MDR-001 is for the treatment of indications such as obesity and type 2 diabetes.

Shanghai Medicilon Inc. (Medicilon), as a strategic partner of MindRank, provided MDR-001 with API process development and preparation R&D services to help speed up its research and development.

Medicilon GLP-1 New Drug R&D Services

One-stop support for new drug development and innovation

From "powerful" hypoglycemic drugs to "miracle" weight-loss drugs, the huge market space of GLP-1 is attracting more attention. As a one-stop biopharmaceutical preclinical research and development service platform, Medicilon has already established a presence in the GLP-1 field, and can provide clients with GLP-1 drug discovery, GLP-1 pharmaceutical research (API process development & preparation), GLP-1 pharmacodynamic research, GLP-1 pharmacokinetic evaluation and GLP-1 safety evaluation.

As of the end of May 2023, Medicilon has successfully assisted 7 GLP-1 drugs to be approved for clinical trials, of which 3 GLP-1 drugs were approved by NMPA/FDA at the same time. There was also another GLP-1 drug was approved by the US FDA, China NMPA and Australia TGA. In addition, there are multiple GLP-1 projects are ongoing under schedule. Relying on rich R&D experience and successful cases, Medicilon has won the trust and affirmation of the clients again and again.

Medicilon congratulates the GLP-1RA small molecule oral drug of MindRank successfully completed the administration of the first subject in clinical phase I. It is hoped that in the next clinical practice, GLP-1RA can send good news to both diabetic and obese patients. Medicilon will also actively embrace new technologies to speed up the new drug development process.

此博客中的热门博文

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客